Catalent, Novo Nordisk

Novo Holdings closes $16.5 billion buyout of contract manufacturer Catalent
Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the Danish drugmaker looks to boost supplies of its widely popular weight-loss drug Wegovy.
Skadden, Goodwin, Davis Polk act as Novo closes $16.5bn Catalent deal
The all-cash deal has involved Novo Holdings acquiring Catalent for $16.5bn, including debt. It will then sell three of Catalent's factories – in Anagni, Italy, Brussels and Bloomington, Indiana – to Novo Nordisk for $11.7bn, enabling the Danish drugmaker to increase production of its obesity and diabetes treatments.
Novo Holdings says its acquisition of Catalent is complete.
Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion.
Novo Holdings completes $16.5 billion takeover of Catalent
Novo Holdings has completed its $16.5 billion takeover of Catalent, the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.
Novo Holdings set to close $16.5B Catalent buy in 'coming days' after deal clears antitrust hurdles
After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.
Novo Holdings Acquires Catalent In $16.5 Bln Cash Deal
Novo Holdings A/S completed the acquisition of Catalent, Inc. (CTLT), a global contract development and manufacturing
STAT3d
Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
pharmaphorum2d
Novo Holdings leads $100m round for novel painkiller biotech
The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for the ...
MM&M3d
Novo Holdings’ $16.5B deal for Catalent clears last regulatory hurdle
Novo Holdings is on track to acquire Catalent, a global contract development and manufacturing organization, in a $16.5 ...
Novo Holdings Completes Acquisition of Catalent
Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment ...
Catalent Acquired by Novo Holdings in $16.5 Billion Deal
The latest announcement is out from Catalent ( (CTLT) ).
Barron's on MSN3d
Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.
The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...
Novo Holdings and SUBRA join forces to accelerate development of innovative superconductor technology for power transmission and fusion energy
Novo Holdings and SUBRA announce a partnership to fast-track the advancement of innovative superconductor technology supported by a convertible loan from Novo Holdings in Danish deep-tech SUBRA.